china glp 1 patent expiry and new GLP‑1 entries intensify global obesity drug fight China Could Approve Lilly Oral

Against that sits ~$535 million in cash, cash equivalents, and short-term investments as of April 30, 2026, with essentially no debt

The Random Forest model (see was configured with 500 trees, and the out-of-bag (OOB) error was used as a quality control metric to evaluate the models performance

NOR test Novel object recognition test was performed during dark hours, in a dimly lighted room as previously described 104 , 1 month after initiation of the treatment

Eli Lilly has since surged ahead with tirzepatide, branded as Mounjaro for diabetes and Zepbound for obesity

Both target dopamine and norepinephrine but through different pathways